B lood-brain barrier (BBB) leakage contributes significantly to the progression of secondary brain injury after ischemic stroke.
B lood-brain barrier (BBB) leakage contributes significantly to the progression of secondary brain injury after ischemic stroke. 1 Although the primary substrate of BBB injury may involve dysfunction in tight junction proteins within the affected endothelium, emerging data now suggest that gliovascular interactions may also be important. Under baseline conditions, astrocytes provide trophic support to cerebral endothelial cells to maintain BBB homeostasis. 2 However, under ischemic conditions, trophic support from astrocytes may be disrupted and furthermore, reactive/diseased astrocytes may even produce deleterious factors that worsen BBB breakdown. 3, 4 Although reactive astrocytes often exert deleterious effects on neighboring cells under pathological conditions, they may also protect brain function or promote brain remodeling after brain injury. 5, 6 In this study, we test our hypothesis that reactive astrocytes may secrete mediators that support BBB function after ischemic stroke. Because one such potential mediator secreted by reactive astrocytes that benefit cerebral endothelial cells, we investigated the roles of pentraxin 3 (PTX3) on BBB integrity. PTX3 is a prototypical member of the long pentraxin family, and it is upregulated in several cardiovascular and cerebrovascular diseases. [7] [8] [9] Therefore, in this study, we first determined whether reactive astrocytes expressed PTX3 after acute ischemic stroke in vivo. Then, primary cell culture experiments were conducted to assess how astrocyte-derived PTX3 may regulate BBB integrity in vitro.
Materials and Methods
All studies were performed following institutionally approved protocols by Massachusetts General Hospital Subcommittee on Research Animal Care, and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Experiments were randomized and blinded and powered to detect effect sizes in the range of 50% to 60%.
Chemicals
Recombinant mouse PTX3 was purchased from R&D systems, recombinant human vascular endothelial growth factor (rVEGF) was purchased from Sigma, and normal rabbit IgG was purchased from Santa Cruz. Mouse PTX3 shows high homology to rat PTX3, and the datasheet describes that mouse PTX3 binds with and activate rat PTX3 receptors.
Animal Model
Ten 3-month-old spontaneous hypertensive male rats (Charles River Laboratories, Wilmington, MA) were used. Rats were anesthetized with isoflurane in 70% N 2 O and 30% O 2 mixture. Rectal temperature was maintained between 36.5°C and 37.5°C with a heating pad. Five rats underwent 75-minute transient middle cerebral artery occlusion (MCAO) by intraluminal filament with ligation of external carotid artery. Five rats underwent 75-minute anesthesia with only ligation of external carotid artery (sham-operated group). Three days after MCAO or sham-operation, rats were deeply anesthetized and perfused with ice-cold saline. Brains were removed and snap frozen. Coronal sections of 20-μm thickness were cut on cryostat (Microm HM505E) at −20°C and collected on the slides and stored at −80°C.
Immunohistochemistry and IgG Staining
Brain sections were fixed by 4% paraformaldehyde and rinsed with PBS. After blocking with 3% BSA, sections were incubated at 4°C overnight in PBS/0.1% Tween solution containing primary antibodies; anti-PTX3 (1:100, Enzo), anti-glial fibrillary acidic protein (GFAP) (astrocyte marker, 1:100, BD Pharm), anti-NeuN (neuron marker, 1:100, Chemicon), anti-platelet-derived growth factor receptor α (oligodendrocyte progenitor cell marker, 1:100, Santa Cruz), anti-platelet-derived growth factor receptor β (pericyte marker, 1:100, R&D systems), anti-nestin (NSC marker, 1:100, abcam), anti-zonula occludens-1 (ZO-1, 1:100, Invitrogen), and anti-VEGF (1:100, Santa Cruz). For IgG staining, sections were incubated overnight at 4°C with antibody against donkey anti-Rat IgG (1:300, Jackson Immunoresearch Laboratories). Then sections were washed and incubated with secondary antibodies with fluorescence conjugations at room temperature for 1 hour. Immunostaining was analyzed with fluorescence microscope (Nikon) interfaced with a digital chargecoupled device camera and an image analysis system. After staining with anti-PTX3 and anti-GFAP antibody and secondary antibodies, MCAO-operated brain section was analyzed on 5 Pascal LSM scanning confocal microscope (Care Zeiss, Germany). Each staining area of PTX3 of peri-infarct area after MCAO was analyzed by quantifying mean intensity, and the staining areas of PTX3, GFAP, IgG, and ZO-1 were analyzed by quantifying mean intensity of divided periinfarct area with a space of 0.2 mm from the core edge for 3 brain sections of each rats, using ImageJ analysis software.
Cell Culture
Rat brain microendothelial cell line RBE.4 cells were maintained in endothelial basal medium-2 (EBM-2) supplemented with EGM-2MV SingleQuots kit (Lonza). Primary astrocyte cultures were prepared from cerebral cortices of 1-to 2-day-old neonatal Sprague-Dawley rats and maintained in DMEM containing 10% fetal bovine serum according to our previous work.
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Preparation of Astrocyte-Conditioned Media
Cultured astrocytes were washed with PBS and maintained in DMEM for 24 hours. Culture medium was then collected and centrifuged at 10 000g for 5 minutes to remove cells and debris. Control media was prepared from culture wells without astrocytes. Astrocyteconditioned media were stored at −80°C until use. For media transfer experiments, astrocyte-conditioned media and control media were diluted with endothelial basal medium-2 at the ratio of 1:1.
Immunoprecipitation
According to the manufacture's instruction, anti-rabbit PTX3 antibody (Enzo) and Dynabeads Protein G Immunoprecipitation kit (Life technologies) were used to precipitate PTX3 in culture media.
In Vitro Endothelial Permeability Assay RBE.4 monolayer was prepared on collagen-I-coated transwells (6.5-mm diameter, 3.0-μm pore size polycarbonate filter, Corning). When RBE.4 became confluent on the transwell, cells were treated with astrocyte-conditioned media or control media for 24 hours. Then, fluorescein isothiocyanate-labeled dextran (molecular weight, 40 000; Sigma) was added to the upper chamber. After 60-minute incubation, 100 μL of culture media from the lower compartment was corrected and measured for fluorescence (excitation, 488 nm and emission, 516 nm) with a spectrophotometer.
Cell Proliferation Assay
Cells were incubated with 10% water soluble tetrazolium solution for 1 hour at 37°C, and then the absorbance of the culture medium was Figure 1 . Pentraxin 3 (PTX3) expression in ischemic brain. Male spontaneously hypertensive rats were subjected to 75-minute middle cerebral artery occlusion (MCAO) followed by 3-day reperfusion. A and B, Western blots showed that PTX3 expression level increased in the MCAO group. Data are represented mean±SD from n=5 per each group. *P<0.05. C, Immunostaining (n=5 each group) confirmed that in the peri-infarct area (ie, cerebral cortex), PTX3 expression was upregulated after MCAO. Scale bar, 50 μm. D, Confocal microscopic observation confirmed that in the peri-infarct area after MCAO, the major cell type for PTX3 production was glial fibrillary acidic protein (GFAP)-positive reactive astrocytes. Scale bar, 50 μm. 
Cell Death Assay
Cytotoxicity was quantified by a standard measurement of lactate dehydrogenase using lactate dehydrogenase assay kit (Roche).
Western Blot
Brain samples of ipsilateral hemisphere from MCAO and shamoperated rats (n=5 each) were homogenized in Pro-PREP Protein Extraction solution (Boca scientific). Cell cultures rinsed twice with ice-cold PBS and then collected into the Pro-PREP. Astrocyteconditioned media were concentrated 10× by using Vivaspin 500 centrifugal concentrator (Vivaproducts). Immunoprecipitation beads were processed according to the manufacturer's instruction for Western blot analysis. Western blot samples were mixed with equal volumes of SDS (Novex) sample buffer containing 10% 2-mercaptoethanol (Sigma). Each sample was loaded into 4% to 20% tris-glycine gels (Novex). After electrophoresis and transferring to nitrocellulose membranes (Novex), the membranes were blocked in I block (Tropix) for 60 minutes and then incubated overnight at 4°C with primary antibodies with ZO-1 (1:1000), claudin 5 (1:500, Santa Cruz), PTX3 (1:1000), VEGF (1:500, Santa Cruz), or β-actin (1:5000, Sigma Aldrich) followed by incubation with peroxidase-conjugated secondary antibodies and visualization with chemiluminescence (GE Healthcare). Optical density was assessed using ImageJ analysis software.
Statistical Analysis
Results were expressed as mean±SD Statistical significance was evaluated using Mann-Whitney U test to compare between 2 groups and Kruskal-Wallis test for multiple comparisons. A P value of <0.05 was considered to be statistically significant.
Results
First, we examined the expression of PTX3 during the acute phase of stroke in vivo. Brain samples from spontaneously hypertensive rats with 75-minute MCAO followed by 3-day reperfusion were subjected to Western blot analysis. PTX3 expression level significantly increased in the MCAO group compared with the sham-operated group ( Figure 1A and 1B) . Then, we conducted immunohistochemistry to identify which cell type(s) expressed PTX3 using cell-specific antibodies such as NeuN for neuron, GFAP for astrocyte, platelet-derived growth factor receptor α for oligodendrocyte progenitor cell, platelet-derived growth factor receptor β for pericyte, and nestin for NSPC. We found that the majority of PTX3-positive cells (87.8±3.7%) was coimmunostained with GFAP in the peri-infarct area ( Figure 1C) , consistent with an astrocytic cellular origin. Furthermore, the confocal microscopic observation confirmed that the GFAP-positive cells exhibited stellate appearance, which is generally thought as a typical morphology of reactive astrocytes ( Figure 1D ).
We next focused on the distribution of PTX3 in the periinfarct area (≈0.8 mm from the core edge). Within that region, GFAP-positive cells were uniformly distributed ( Figure I in the online-only Data Supplement). However, IgG staining indicative of BBB leakage was mainly observed in the periinfarct areas close to the edge of the infarct core, whereas PTX3 was strongly immunostained in the peri-infarct areas farthest away from the edge of the infarct core ( Figure  2A-2C) . The level of PTX3 expression exhibited significant negative correlation with the IgG leakage in the peri-infarct area ( Figure 2D ), raising the possibility that astrocytic PTX3 may be involved in the regulation of BBB permeability during acute stroke in vivo.
To further examine how astrocyte-derived PTX3 may regulate BBB function, we conducted in vitro cell culture experiments using primary rat astrocytes and RBE.4 rat brain endothelial cells. Western blots of astrocyte-conditioned media (ACM) confirmed that cultured astrocytes secreted PTX3 ( Figure 3A ; left lane). To investigate the role of astrocyte-derived PTX3 in the context of BBB permeability, we measured endothelial permeability in a standard transwell system, either in the presence of normal ACM or PTX3-depleted ACM (ACM PTX3-obtained by filtering ACM with anti-PTX3 antibody- Figure 3A ; right lane). As expected, normal ACM decreased endothelial permeability (ie, astrocytes enhanced the endothelial tightness in vitro; Figure 3B ). But the PTX3-depleted ACM PTX3-did not enhance endothelial tightness ( Figure 3B) . Notably, ACM-derived PTX3 was also supportive for in vitro BBB tightness under pathological conditions ( Figure II in the online-only Data Supplement). These effects of PTX3 might be attributed to paracellular mechanisms because ACM containing PTX3 significantly increased the expression levels of tight junction proteins ZO-1 and claudin 5, whereas PTX3-depleted ACM did not ( Figure 4A-4C) .
To confirm the direct endothelial barrier-tightening effect of PTX3, we added recombinant PTX3 to brain endothelial cells and examined the permeability and expression levels of ZO-1 and claudin 5. Exogenous PTX3 significantly enhanced endothelial barrier tightness along with increasing expression of ZO-1 and claudin 5 ( Figure 5A-5D ). Water soluble tetrazolium and lactate dehydrogenase assays confirmed that PTX3 did not affect the cell number and cell viability in the cultured endothelial layers ( Figure III in the online-only Data Supplement). These in vitro findings were supported by our in vivo data, demonstrating that ZO-1 expression pattern was mildly correlated with PTX3 expression in the peri-infarcted region ( Figure IV in the online-only Data Supplement).
PTX3 is known to bind to VEGF, 12 which is a key regulator of endothelial leakage during stroke. Therefore, we asked whether BBB-protecting effects of PTX3 may also involve VEGF in our model systems. Indeed, in our in vivo rat stroke model, VEGF expression increased after ischemia and reactive astrocytes indeed produced both VEGF and PTX3 ( Figure V in the online-only Data Supplement). Immunoprecipitation assays confirmed that recombinant PTX3 directly bound to VEGF in cell-free conditions ( Figure 6A ). Similarly, we confirmed that astrocyte-derived PTX3 bound to VEGF in the conditioned media from astrocyte cultures ( Figure 6B ). Finally, exogenous PTX3 suppressed the VEGF-mediated increase in cerebral endothelial cell permeability in vitro ( Figure 6C ), suggesting that PTX3 may negatively regulate VEGF actions on BBB permeability by directly binding and capturing VEGF.
Discussion
In this study, we described a novel role of astrocytes in supporting BBB integrity during the acute phase of ischemic stroke. Within the neurovascular unit, astrocytes are the major cell type to maintain cerebrovascular homeostasis. In the brain, astrocytes enfold blood vessels with multiple endfeet 13 and release several trophic factors that support BBB function under normal conditions. 14 For example, astrocyte-derived glial-derived neurotrophic factor enhances the barrier function of BBB. 15 On the other hand, after brain injury, reactive astrocytes secrete deleterious factors, such as VEGF, that cause BBB breakdown. 16 However, recent studies suggest that reactive astrocytes may also contribute to BBB protection under pathological conditions. 17, 18 Our current study supports the idea that reactive astrocytes may have beneficial actions after ischemic stroke, that is, astrocyte-derived PTX3 protects BBB integrity during ischemic conditions ( Figure 6D ).
The pentraxins belong to a superfamily of multifunctional proteins 19 with conserved phylogeny. They are divided into 2 groups based on their primary structure: short and long pentraxin.
20 PTX3 belongs to a long pentraxin family and is upregulated by inflammatory stress. Thus far, several kinds of cell types are confirmed to produce PTX3-vascular endothelial cells, 21, 22 vascular smooth muscle cells, 23 and monocytes/ macrophages. 24, 25 Recent cell culture studies also showed that neurons and mixed glial cells may secrete PTX3 after interleukin-1α/β (IL-1α/β) stimulation. 26 Those inflammationinduced PTX3 may have protective roles because PTX3 can reduce acute myocardial infarction, 27 lung injury, 28 and acute kidney injury. 29 Furthermore, PTX3 knockout mice exhibited severe edema formation and glial scar formation under ischemic conditions. 26 Our findings filled the gap of knowledge of PTX3 roles in stroke conditions-(1) reactive astrocytes are the major cell type for PTX3 production in the peri-infarct area, (2) astrocytic PTX3 may support BBB integrity, and (3) PTX3 increases expression levels of tight junction proteins in cerebral endothelial cells. Therefore, these results may provide an important insight for a compensatory response of reactive astrocytes after brain injury.
Another important finding of our current study is that PTX3 may support BBB integrity in both direct and indirect ways. Under stroke conditions, several deleterious factors, such as VEGF, are released to cause BBB dysfunction. As one of the early events after central nervous system injury and inflammation, VEGF breaks down BBB integrity by downregulating protein and mRNA levels of claudin 5 and occludin, which are important components of the BBB. 30 Our findings may arouse the novel concept that PTX3 counteracts the negative effects of VEGF on the BBB. Importantly, Rusnati et al 12 previously demonstrated that PTX3 has high affinity to fibroblast growth factor (FGF) 2 and blocks FGF2-induced angiogenesis in vitro. The same study showed that PTX3 has low or no affinities to a panel of cytokines and growth factors, including FGF-1, nerve growth factor, or IL-1. But interestingly, PTX3 exhibited an affinity to VEGF to some extent, which supports our idea that PTX3 interacts with VEGF and supports the BBB integrity during the acute phase of stroke. However, our current study only demonstrated the interaction of PTX3 with VEGF. To understand the roles of PTX3 in ischemic brains more precisely, we may need to carefully examine whether PTX3 interacts with other BBB-damaging factors in future studies. Although our findings describe a novel role of astrocytic PTX3 in cerebral ischemia, we need to note a few caveats and limitations in this proof-of-concept study. First, PTX3 expression pattern in peri-infarct area was negatively correlated to the IgG leakage (ie, BBB damage) in our stroke rats. But strictly speaking, we have not provided a direct proof that astrocytic PTX3 protects BBB against ischemic stress in vivo. Future studies may require gain and loss-of-function studies of PTX3 in astrocytes in vivo to confirm our in vitro findings that astrocyte-derived PTX3 increases tight junction protein expressions and decreases the endothelial permeability. Second, not all the reactive astrocytes expressed PTX3 in the peri-infarct area; consistent with the well-known heterogeneous nature of astrocytes. Which factors or signaling pathways regulate PTX3 expression in reactive astrocytes would be an important research topic in future. Third, reactive astrocytes are one of the major cell types for PTX3 production in brain parenchyma, but as mentioned above, circulating cells such as monocytes and macrophages also secrete PTX3. How circulating cell-derived PTX3 contribute to cerebrovascular function under ischemic stroke is an important area of future investigations. Fourth, our cell culture experiments described an important role of PTX3 on paracellular pathway of BBB breakdown, but after stroke, transcellular pathways may also be important. 31 Whether and how PTX3 contributes to the transcellular pathway of BBB should also be examined in future to understand the roles of PTX3 on cerebrovascular function more carefully. Finally, our current study focused only on the acute phase of stroke. Although VEGF (or other BBB-damaging factors) is deleterious during the acute phase of stroke, it is beneficial during the chronic phase because it promotes brain remodeling. 32 Because PTX3 inhibited VEGF effects in endothelial cultures, it is possible that astrocytic PTX3 would, in turn, inhibit brain repair, especially compensatory angiogenesis, after stroke. In fact, past studies demonstrate that PTX3 inhibits in vitro angiogenesis by FGF2 or FGF8 treatment. 12, 33, 34 Therefore, the effects and dynamic roles of PTX3 on angiogenesis should be carefully assessed to further delineate the therapeutic potential of PTX3 for stroke or other cerebrovascular diseases.
In summary, our present study demonstrates that PTX3 is an important mediator from reactive astrocytes that acts on cerebral endothelial cells and supports BBB integrity after ischemic stroke. This finding reveals a novel role of reactive astrocytes under pathological conditions and suggests that astrocytic PTX3 may be an effective therapeutic target for acute ischemic stroke. Figure III 
